WO2023033174A1 - 水溶性フィチン - Google Patents
水溶性フィチン Download PDFInfo
- Publication number
- WO2023033174A1 WO2023033174A1 PCT/JP2022/033286 JP2022033286W WO2023033174A1 WO 2023033174 A1 WO2023033174 A1 WO 2023033174A1 JP 2022033286 W JP2022033286 W JP 2022033286W WO 2023033174 A1 WO2023033174 A1 WO 2023033174A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phytin
- calcium
- phytic acid
- composition
- magnesium
- Prior art date
Links
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 title claims abstract description 436
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 131
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 128
- 229940068041 phytic acid Drugs 0.000 claims abstract description 115
- 239000000467 phytic acid Substances 0.000 claims abstract description 115
- 239000011575 calcium Substances 0.000 claims abstract description 96
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 80
- 239000011777 magnesium Substances 0.000 claims abstract description 65
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims description 148
- 230000002401 inhibitory effect Effects 0.000 claims description 63
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 49
- 150000003212 purines Chemical class 0.000 claims description 47
- 238000010521 absorption reaction Methods 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 40
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 38
- 239000008280 blood Substances 0.000 claims description 36
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000002213 purine nucleotide Substances 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 33
- 239000011734 sodium Substances 0.000 claims description 31
- 230000037360 nucleotide metabolism Effects 0.000 claims description 29
- 235000000346 sugar Nutrition 0.000 claims description 28
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 27
- 229910052708 sodium Inorganic materials 0.000 claims description 27
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 26
- 239000011591 potassium Substances 0.000 claims description 26
- 229910052700 potassium Inorganic materials 0.000 claims description 26
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 25
- 239000011707 mineral Substances 0.000 claims description 25
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 24
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 24
- 229940116269 uric acid Drugs 0.000 claims description 24
- 230000036772 blood pressure Effects 0.000 claims description 22
- 229910052742 iron Inorganic materials 0.000 claims description 19
- 230000003908 liver function Effects 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 11
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 11
- 206010020590 Hypercalciuria Diseases 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 description 30
- 238000012360 testing method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000843 powder Substances 0.000 description 19
- 230000006872 improvement Effects 0.000 description 15
- 230000001629 suppression Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 12
- 229910019440 Mg(OH) Inorganic materials 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000002212 purine nucleoside Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011870 unpaired t-test Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013902 inosinic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- IXHBSOXJLNEOPY-UHFFFAOYSA-N 2'-anilino-6'-(n-ethyl-4-methylanilino)-3'-methylspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C=C(C2(C3=CC=CC=C3C(=O)O2)C2=CC(NC=3C=CC=CC=3)=C(C)C=C2O2)C2=CC=1N(CC)C1=CC=C(C)C=C1 IXHBSOXJLNEOPY-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000016019 chocolate confectionery Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- This application relates to phytin with improved water solubility and compositions containing it.
- Phytic acid has a chelating action and an antioxidant action, and is also known to have an anticoagulant action, an action to prevent hypercalciuria, and an action to improve lipids. Furthermore, Patent Document 2 discloses that phytic acid has a purine nucleotide metabolism inhibitory action and a phosphatase inhibitory action, and has an effect of suppressing an increase in serum uric acid level in humans. In addition, Patent Document 2 also describes the effect of phytic acid on improving blood pressure and improving blood sugar level. Phytic acid is usually in a liquid state, but it is commercially available in the form of powdered phytic acid (phytic acid powder product (50%)), which is made by adding excipients to phytic acid for easier processing.
- phytic acid powder product 50%
- phytin which is a mineral salt of phytic acid such as calcium and magnesium, is commercially available in the form of powder, but is stable without deliquescence.
- Phytin is a general term for mineral salts, and does not mean that the types and molar ratios of mineral components such as calcium and magnesium are constant, but actually exist naturally in rice, corn, wheat, oats, etc.
- Non-Patent Document 1 The molar ratio of mineral components such as magnesium and calcium in phytin is not constant (Non-Patent Document 1). Phytin is expected to have various pharmacological/health-promoting effects due to its constituent phytic acid, but none of the known phytins dissolves in water (Non-Patent Document 2). It is not suitable for use in formulations that require good water solubility, such as granules dissolved in water.
- Yoshida KT Wada T, Koyama H, Mizobuchi-Fukuoka R, Naito S. Temporal and spatial patterns of accumulation of the transcript of Myo-inositol-1-phosphate synthase and phytin-containing particles during seed development in rice. Plant Physiol. 1999 ; 119(1):65-72. Plimmer RH, et al., Biochem J. 1913;7(2):157-74.
- An object of the present invention is to provide phytin with improved water solubility, a method for producing the same, and a composition containing the phytin.
- the present inventors conducted intensive studies to solve the above problems, and surprisingly found that phytin having a molar ratio of magnesium and calcium to phytic acid within a specific range has a very high solubility in water. , completed the invention of the present disclosure. Still more surprisingly, existing commercially available water-insoluble phytin has lower purine nucleotide metabolism inhibitory activity than phytic acid, but phytin with a specific range of molar ratios of magnesium and calcium to phytic acid is commercially available. It was also found that the purine nucleotide metabolism inhibitory activity is higher than that of water-insoluble phytin, and that it has activity equal to or greater than that of phytic acid.
- 0 ⁇ p ⁇ 4 for example, 0.5 ⁇ p ⁇ 3, 0.5 ⁇ p ⁇ 2, 0.5 ⁇ p ⁇ 1.5, 0.5 ⁇ p ⁇ 1.2
- 0 ⁇ q ⁇ 6 e.g., 0.5 ⁇ q ⁇ 3, 0 .5 ⁇ q ⁇ 2, 0.5 ⁇ q ⁇ 1.5, 0.5 ⁇ q ⁇ 1.2
- p and q are not zero.
- a composition for suppressing purine absorption, comprising the phytin according to any one of [1] to [9].
- the composition for inhibiting purine absorption of [11] wherein the purine absorption is through the intestinal tract.
- a purine nucleotide metabolism inhibitory composition comprising the phytin of any one of [1] to [9].
- a phosphatase inhibitory composition comprising the phytin of any one of [1] to [9].
- a composition for suppressing an increase in uric acid level containing the phytin according to any one of [1] to [9].
- a blood pressure-improving composition comprising the phytin of any one of [1] to [9].
- a blood sugar level-improving composition comprising the phytin of any one of [1] to [9].
- a composition for preventing hypercalciuria containing the phytin of any one of [1] to [9].
- phytic acid In the mixing step, phytic acid; mixing a magnesium source (e.g. Mg(OH) 2 ) and/or a calcium source (e.g. Ca(OH) 2 ); and a potassium source (e.g. KOH) and/or a sodium source (e.g. NaOH) in the presence of water, [22] The production method according to any one of [28]. [30] phytic acid in the mixing step; a magnesium source (e.g. Mg(OH) 2 ) and/or a calcium source (e.g. Ca(OH) 2 ); and a potassium source (e.g. KOH) and/or a sodium source (e.g.
- NaOH sodium OH
- the production method is mixed in the presence of water and excipients, the production method according to any one of [22] to [29].
- [31] When the amount of potassium (C) is p mol and the amount of sodium (D) is q mol per 1.8 mol of phytic acid in the mixture, 0 ⁇ p ⁇ 4 (for example, 0.8 mol). 5 ⁇ p ⁇ 3, 0.5 ⁇ p ⁇ 2, 0.5 ⁇ p ⁇ 1.5, 0.5 ⁇ p ⁇ 1.2) and 0 ⁇ q ⁇ 6 (for example, 0.5 ⁇ q ⁇ 3, 0.5 ⁇ q ⁇ 2, 0.5 ⁇ q ⁇ 1.5, 0.5 ⁇ q ⁇ 1.2) and both p and q are not 0, [29] or [30 ].
- [35] purine body absorption inhibitory composition, purine nucleotide metabolism inhibitory composition, phosphatase inhibitory composition, uric acid level increase inhibitory composition, blood pressure improving composition, blood sugar level improving composition, liver function improving composition, serum iron adjusting composition The use of phytin according to any one of [1] to [9] in the production of a product, a composition for promoting calcium absorption, a composition for preventing hypercalciuria, and a lipid-improving composition.
- a method for suppressing absorption of purines a method for inhibiting purine nucleotide metabolism, comprising administering a composition containing phytin according to any one of [1] to [9]; method of inhibiting, method of suppressing increase in uric acid level, method of improving blood pressure, method of improving blood sugar level, method of improving liver function, method of adjusting serum iron, method of promoting calcium absorption, hypercalciuria methods of preventing disease, improving lipid levels, and preventing deterioration of lipid levels.
- [37] Use in suppression of purine absorption, inhibition of purine nucleotide metabolism, phosphatase inhibition, suppression of uric acid level increase, improvement of blood pressure, improvement of blood sugar level, improvement of liver function, regulation of serum iron, promotion of calcium absorption, prevention of hypercalciuria, or improvement of lipids
- the phytin according to any one of [1] to [9] for Two or more of the configurations [1] to [37] can be arbitrarily selected and combined.
- the present invention provides phytin with improved water solubility, a method for producing the same, and a composition containing the phytin.
- Fig. 1 shows the test results of test example 1 solubility.
- the horizontal axis indicates the molar ratio of Ca to 1.8 mol of phytic acid.
- the vertical axis indicates the molar ratio of Mg to 1.8 mol of phytic acid.
- 2-1 shows the results of the purine nucleotide metabolism inhibitory activity test of Test Example 2.
- FIG. Each column shows the mean ⁇ standard error, and the asterisk indicates P ⁇ 0.05 (vs PA, unpaired t-test).
- 2-2 shows the results of the purine nucleotide metabolism inhibitory activity test of Test Example 2.
- FIG. Each column shows the mean ⁇ standard error, and the asterisk indicates P ⁇ 0.05 (vs PA, unpaired t-test).
- FIG. 2-3 shows the results of the purine nucleotide metabolism inhibitory activity test of Test Example 2.
- FIG. Each column shows the mean ⁇ standard error, and the asterisk indicates P ⁇ 0.05 (vs PA, unpaired t-test).
- 2-4 shows the results of the purine nucleotide metabolism inhibitory activity test of Test Example 2.
- FIG. Each column shows the mean ⁇ standard error, and the asterisk indicates P ⁇ 0.05 (vs PA, unpaired t-test).
- 2-5 shows the results of the purine nucleotide metabolism inhibitory activity test of Test Example 2.
- FIG. Each column shows the mean ⁇ standard error, and the asterisk indicates P ⁇ 0.05 (vs PA, unpaired t-test).
- FIG. 3 shows the stability (deliquescent) test results of commercial products (powder phytic acid and phytin) in Test Example 3. Top row: powdered phytic acid. Bottom row: phytin.
- the present invention provides phytin with improved water solubility (hereinafter sometimes referred to as phytin of the present invention) containing (A) calcium and/or (B) magnesium.
- phytoen means a mineral salt of phytic acid, which is a hexaphosphate ester of myo-inositol, the mineral containing magnesium, calcium, or both.
- the minerals may further contain potassium, sodium and the like.
- a water solubility test method is not particularly limited. For example, it can mean phytin in which turbidity or precipitation cannot be visually confirmed when tested by the method of Test Example 1 of the present invention.
- phytin in which precipitation cannot be visually confirmed by repeating a mixing operation of adding phytin (10 mg/ml) to water (20 to 25° C.), vortexing for 30 seconds and sonicating for 60 seconds in total three times.
- the phytin with improved water solubility of the present invention may contain other mineral components (eg, potassium and sodium) in addition to calcium and magnesium, as long as the phytin exhibits improved water solubility. good.
- the phytin of the present invention is water-soluble phytin.
- water-soluble phytin means phytin that is soluble in water.
- water-soluble phytin is obtained by adding phytin (10 mg/ml) to water (20-25°C), repeating the mixing operation of vortexing for 30 seconds and sonicating for 60 seconds three times, and measuring the resulting mixture with a spectrophotometer.
- OD600 value when the optical density (OD) at 600 nm is measured at 600 nm and having no visible turbidity or precipitation.
- it can mean phytin that has an OD600 value of 0.008 or less and no precipitation can be visually confirmed when tested by the method of Test Example 1 of the present invention.
- the water-soluble phytin of the present invention may contain other mineral components (eg, potassium and sodium) in addition to calcium and magnesium, as long as the
- the phytin of the present invention contains (A) calcium and/or (B) magnesium, and in the phytin, the substance amount of (A) calcium per 1.8 mol of phytic acid is x mol, ( B) 0 ⁇ x ⁇ 2, 0 ⁇ y ⁇ 6, and both x and y are not zero, where y mol is the substance amount of magnesium.
- the phytin of the present invention contains (A) calcium and/or (B) magnesium, and in the phytin, the substance amount of (A) calcium per 1.8 mol of phytic acid is x mol, ( B) 1.4x+y ⁇ 5.4 (x ⁇ 0, y ⁇ 0, provided that both x and y are not 0), where y mol is the substance amount of magnesium.
- the phytin of the present invention further contains (C) potassium and/or (D) sodium.
- the phytin of the present invention further comprises (C) potassium and/or (D) sodium, and in the phytin, the substance amount of (C) potassium per 1.8 mol of phytic acid is pmol, (D) 0 ⁇ p ⁇ 4, 0 ⁇ q ⁇ 6, and p and q are not zero, where q mol is the substance amount of sodium.
- Non-Patent Document 2 Plimmer RH, et al., Biochem J. 1913;7(2):157-74.
- the physical amount of magnesium per 8 moles and the physical amount of calcium are shown.
- conventional phytin is a white, water-insoluble neutral powder, non-deliquescent and excellent in stability.
- the phytin of the present invention is not phytin contained in wheat.
- the phytin of the present invention is not phytin contained in natural products (eg, wheat, corn, oats, rice).
- the method for producing phytin of the present invention is not particularly limited, it can be produced, for example, by the production method described below as one aspect of the present invention.
- the invention provides: phytic acid; and a source of magnesium and/or calcium; and a drying step of drying the resulting mixture (hereinafter sometimes referred to as the production method of the present invention).
- the substance amount of (A) calcium is x mol and the substance amount of (B) magnesium is y mol per 1.8 mol of phytic acid contained in the mixture. , 1.4x+y ⁇ 5.4 (x ⁇ 0, y ⁇ 0, where both x and y are not 0).
- the substance amount of (A) calcium is x mol and the substance amount of (B) magnesium is y mol per 1.8 mol of phytic acid contained in the mixture. when 0 ⁇ x ⁇ 2, 0 ⁇ y ⁇ 6, and both x and y are not zero.
- the mixing step further includes a potassium source and/or a sodium source.
- the production method of phytic acid used in the production method of the present invention is not particularly limited. Extracts, partially purified products, and processed products may also be used. Phytic acid isolated from their extracts, partially purified products, and processed products can also be used. Phytic acid may be prepared in advance as an aqueous solution and mixed with other raw materials.
- the concentration of phytic acid contained in the mixture is not particularly limited. mL).
- magnesium source means an electrolyte capable of providing Mg 2+ in water.
- the magnesium source may be used as it is, or may be previously prepared as an aqueous solution and mixed with other raw materials.
- the magnesium source is Mg(OH) 2 .
- a calcium source means an electrolyte capable of providing Ca 2+ in water.
- the calcium source may be used as it is, or may be prepared as an aqueous solution in advance and mixed with other raw materials.
- the calcium source is Ca(OH) 2 .
- potassium source means an electrolyte that can provide K + in water.
- the potassium source may be used as it is, or may be previously prepared as an aqueous solution and mixed with other raw materials.
- the potassium source is KOH.
- sodium source means an electrolyte capable of providing Na + in water.
- the sodium source may be used as it is, or may be prepared as an aqueous solution in advance and mixed with other raw materials.
- the sodium source is NaOH.
- the mixing step is performed in the presence of water and excipients.
- excipients include dextrin, starches (eg, potato starch, corn starch), cellulose, sugars (eg, lactose, white sugar, trehalose).
- starches eg, potato starch, corn starch
- sugars eg, lactose, white sugar, trehalose.
- One type of excipient may be used, or multiple types of excipients may be used.
- the excipient is dextrin.
- the pH of the mixture is 3.0-5.0 (preferably 3.5-4.5, more preferably 3.8-4.2) and optionally HCl etc. can be adjusted.
- the mixing time in the mixing step is not particularly limited, and mixing is preferably continued until a clear solution is obtained, for example, 1 to 1.5 hours.
- the drying method in the drying step of the production method of the present invention is not particularly limited, and a method commonly used in the field (for example, freeze drying) can be used.
- the production method of the present invention may optionally include additional steps such as filtration and pulverization. Further additives may be added in the production method of the present invention as long as they do not affect the solubility of phytin.
- phytin produced by the production method of the present invention may also be referred to as phytin of the present invention.
- the phytin of the present invention contains calcium (A) and/or magnesium (B) in a predetermined ratio.
- the contents of calcium (A) and magnesium (B) are not particularly limited as long as the effects of the present invention such as improved solubility are exhibited.
- the amounts of calcium (A) and magnesium (B) per 1.8 mol of phytic acid contained in phytin are expressed by the following formula, where x and y are the amounts of the respective substances: 1.4 x + y ⁇ 5.4 satisfies (x ⁇ 0, y ⁇ 0, where both x and y are not 0). More preferably, the range is 0.3 ⁇ x ⁇ 1.07 and 3.9 ⁇ y ⁇ 4.98.
- 4.5 ⁇ (or ⁇ ) y ⁇ (or ⁇ ) 5 is excluded from the range of y.
- 0.5 ⁇ 1.4x+y ⁇ 5.4 (x ⁇ 0, y ⁇ 0, where both x and y are not 0).
- 2.5 ⁇ 1.4x+y ⁇ 5.4 (x ⁇ 0, y ⁇ 0, where both x and y are not 0).
- a composition containing phytin of the present invention (hereinafter sometimes referred to as a composition of the present invention) is provided.
- a composition such as a powder with improved water solubility can be provided.
- the phytin of the present invention can have an enzyme inhibitory activity equal to or greater than that of phytic acid, it can be used as a substitute for phytic acid in phytic acid-containing compositions.
- Phytine is a highly safe substance with abundant food experience, and is suitable for long-term and continuous intake. According to the present invention, by making a solid composition such as a powder composition, the portability is improved and the convenience is increased, so that long-term and continuous intake can be made possible.
- the phytin of the present invention can also be non-deliquescent. Due to its deliquescence due to phytic acid, its storage stability is low, and its use in solid formulations is difficult. On the other hand, the non-deliquescent phytin of the present invention has excellent storage stability and can have an activity equal to or equal to or greater than that of phytic acid. It can be suitable for use in solid formulations (for example, powders, granules, tablets, tablets, etc.) that are difficult to formulate.
- x+y>0.1, preferably x+y>0.3, more preferably x+y>0.5, even more preferably x+y ⁇ 1. is 0.
- a purine body absorption inhibitory composition a purine nucleotide metabolism inhibitory composition, a phosphatase inhibitory composition, a uric acid level elevation inhibitory composition, a blood pressure improving composition, and a blood sugar level improving composition containing the phytin of the present invention.
- a liver function-improving composition a serum iron-regulating composition, or a calcium absorption-enhancing composition.
- a method for inhibiting absorption of purines comprising administering a composition containing phytin of the present invention (e.g., a solid composition (e.g., powder, granules)), inhibiting purine nucleotide metabolism method, method of inhibiting phosphatase, method of inhibiting uric acid elevation, method of improving blood pressure, method of improving blood sugar level, method of improving liver function, method of regulating serum iron, or method of promoting calcium absorption I will provide a.
- a composition containing phytin of the present invention e.g., a solid composition (e.g., powder, granules)
- the phytate of the present invention may contain mineral components other than calcium (A) and magnesium (B) within a range that does not inhibit the effects of the present invention.
- the phytin of the present invention is substantially free of mineral components other than calcium, magnesium, potassium, and sodium.
- the amount of phytate contained in the composition of the present invention (food, drink, pharmaceutical composition, etc.), the amount of phytate administered per administration, and the amount of phytate administered per day are determined according to the desired There is no particular limitation as long as the effect is exhibited, and it can be appropriately selected according to the form of the composition, the frequency of administration, the health condition of the subject, and the like.
- the administration period of the composition of the present invention is not particularly limited as long as the desired effect is exhibited, and the composition may be administered once or continuously.
- composition of the present invention is desirably taken continuously over a long period of time, which can be, for example, 2 days, 3 days, 1 week, 10 days, 1 month, or 3 months or more.
- the amount of phytin incorporated in the composition of the present invention varies depending on the type of phytin, the form of the composition, and the like. % to 90% by weight. Examples include 0.5 wt% to 90 wt%, 0.5 wt% to 85 wt%, 0.5 wt% to 80 wt%, 1 wt% to 70 wt%, and 1 wt% to 50 wt%. be. Further examples of the upper limit of the content of phytin contained in the composition of the present application are 90% by weight, 85% by weight, 80% by weight, 70% by weight, 50% by weight, 30% by weight, relative to the total weight of the composition.
- the amount of phytin incorporated in the composition of the present invention is for example, it can be appropriately selected from the range of 1 to 90% by weight. Preferred examples are 1% to 90% by weight, 5% to 80% by weight, 10% to 70% by weight, and 50% to 70% by weight.
- the upper limit of the content of phytin in the composition of the present application when the composition of the present invention is formulated as a solid preparation such as a tablet, granule, capsule, powder, or chewable tablet With respect to the total weight of the composition, preferably 90% by weight, 85% by weight, 80% by weight, 70% by weight, and 50% by weight; Further examples include preferably 1%, 5%, 10% and 20% by weight relative to the total weight of the composition; A preferred range can be indicated by a combination of the upper limit and the lower limit.
- composition of the present invention varies depending on the type of phytin, 10 mg to 15 g, preferably 100 mg to 8 g, more preferably 300 mg to 5 g of phytic acid can be administered per administration.
- the lower limit of the intake of phytin per dose include 10 mg, 100 mg, 300 mg, 500 mg, and 600 mg of phytic acid
- examples of the upper limit of the intake of phytic acid are 15 g, 10 g, 8 g, 5 g, and 3 g. , 2 g, 1 g, and 600 mg
- a preferred range of intake of phytin per dose can be indicated by a combination of the upper limit and the lower limit.
- 10 mg to 15 g, preferably 100 mg to 8 g, more preferably 300 mg to 5 g of phytic acid can be administered per day, although this varies depending on the type of phytin.
- the lower limit of the daily intake of phytin include 10 mg, 100 mg, 300 mg, 500 mg, and 600 mg of phytic acid
- examples of the upper limit of the daily intake of phytic acid are 15 g, 10 g, 8 g, 5 g, and 3 g. , 2 g, 1 g, and 600 mg
- a preferred range of intake of phytin per day can be indicated by a combination of the upper limit and the lower limit.
- Phytin, which can be administered per day may be administered in a single dose or in multiple doses (eg, 2, 3, 4, and 5).
- ⁇ Analysis method> The content of phytate contained in the composition of the present invention can be analyzed by general analytical methods known to those skilled in the art. Examples include, but are not limited to, ion chromatography and vanadomolybdic acid absorbance.
- the timing of ingestion of the composition of the present invention is not particularly limited, but it is preferably ingested with a meal, or within 30 minutes before or after a meal.
- composition of the present invention is preferably formulated as an orally ingested formulation, and the formulation type is not particularly limited.
- composition of the present invention can be formulated into an orally ingested preparation by adding pharmaceutically acceptable bases and carriers, additives that can be used in foods, and the like.
- Materials other than phytin used in the composition of the present invention desirably do not impair the stability of phytin, and further desirably do not impair the intended effects of the composition of the present invention.
- the composition of the present invention can be a food or drink or a pharmaceutical composition, and can be used as a food or drink such as a food with function claims, a food for specified health use, a health food, a nutritional supplement (supplement), or a medical food.
- purine bodies is a general term for compounds having a common structure called a purine skeleton, which perform various functions in vivo, such as transmitting genetic information as constituents of nucleic acids.
- Purine bodies include purine bases (e.g., adenine, guanine, hypoxanthine), purine nucleosides in which sugars are attached to purine bases (e.g., adenosine, guanosine, inosine), and purine nucleotides in which a phosphate group is attached to purine nucleosides (e.g., adenyl acid (AMP), guanylic acid (GMP), inosinic acid (IMP)).
- AMP adenyl acid
- GMP guanylic acid
- IMP inosinic acid
- purine absorption means that the purines (purine bases, purine nucleosides, purine nucleotides, or nucleic acids containing purine nucleotide residues (e.g., oligonucleotides, polynucleotides)) are absorbed into the body depending on the form of the purines. It means that it is absorbed into the body via metabolism in the body.
- purines purine bases, purine nucleosides, purine nucleotides, or nucleic acids containing purine nucleotide residues (e.g., oligonucleotides, polynucleotides)
- suppression of purine absorption means a relative decrease in purines (eg, dietary purines) absorbed into the body (eg, absorbed from the intestinal tract).
- the “suppression of purine absorption” includes, for example, inhibition of alkaline phosphatase and/or 5' nucleotidase to prevent conversion of purine nucleotides to purine nucleosides (which results in purine absorption into the body). decreases).
- dietary purines means purines derived from food and beverages when ingested.
- “Intestinal absorbable purines” in the present invention include purine bases and purine nucleosides.
- inhibitortion of purine nucleotide metabolism means inhibition of conversion of purine nucleotides to purine nucleosides.
- phosphatase inhibition means inhibition of phosphatase activity involved in purine metabolism, for example, inhibition of alkaline phosphatase and/or 5'nucleotidase.
- suppression of uric acid level elevation means suppression of an excessive increase in uric acid level. If the serum uric acid level is normal or low, maintain the serum uric acid level, or prevent the serum uric acid level from increasing or alleviate the increase. For example.
- a composition for suppressing an increase in uric acid level is exemplified, in which the dose of phytin per dose is 10 mg to 15 g as phytic acid.
- blood pressure improvement means suppression of excessive increase in blood pressure. , or attenuate elevation, maintain blood pressure in normal and hypotensive individuals, prevent or attenuate elevation of blood pressure.
- blood sugar level improvement means suppression of an excessive increase in blood sugar level. This includes lowering or moderating elevations, maintaining blood glucose levels in normo- and hypoglycemic individuals, and preventing or mitigating elevations in blood glucose levels.
- improved liver function means that liver function is improved, and for example, the function can be indicated by an index (eg, AST: aspartate aminotransferase).
- index eg, AST: aspartate aminotransferase
- improved liver function includes lowering or alleviating the increase in blood AST levels in persons with high blood AST levels (including those with normal but high blood AST levels); This includes maintaining blood AST levels in those who are not healthy, preventing blood AST levels from rising, or mitigating the rise of blood AST levels.
- serum iron adjustment means suppression of an excessive increase or decrease in serum iron level. If you have a low serum iron level (including those who are normal but have a low level), increase your serum iron level This includes maintaining serum iron levels in normal iron levels, preventing serum iron levels from rising or falling, or mitigating the rise or fall of serum iron levels.
- promoting calcium absorption means promoting absorption of calcium from the intestinal tract.
- “enhancement of calcium absorption” includes an increase in the blood concentration of active vitamin D (1,25-(OH)2-D), which promotes absorption of calcium from the intestinal tract.
- composition for suppressing purine absorption the composition for inhibiting purine nucleotide metabolism, the composition for inhibiting phosphatase, the composition for suppressing increase in uric acid level, the composition for improving blood pressure, the composition for improving blood sugar level, the composition for improving liver function, and the composition for adjusting serum iron of the present invention
- the product or the calcium absorption-enhancing composition-reducing composition has these predetermined uses (purine nucleotide metabolism inhibition, phosphatase inhibition, uric acid level increase suppression, blood pressure improvement, blood sugar level improvement, liver function improvement, serum iron adjustment, or calcium absorption promotion).
- the prescribed use of the drug product is indicated on the main body of the drug product, packaging, instructions, pamphlets, containers, advertising materials, advertising materials at sales sites such as POP, other documents, etc., electromagnetic methods, etc. (Internet, etc.).
- composition for suppressing purine absorption or the composition for suppressing an increase in uric acid level of the present invention it is useful for "those who are concerned about purines in their diet", “fighting purines", and “eating a diet rich in purines”.
- the scope of the present invention also includes foods and beverages describing expressions suggestive of suppression of purine absorption or suppression of increase in uric acid level, such as "For those who tend to be prone” and "For those who are concerned about postprandial uric acid levels.”
- the blood pressure-improving composition of the present invention it is "suitable for people with high blood pressure”, “supports healthy blood pressure”, “has an effect of lowering high blood pressure”, “for those who are concerned about blood pressure”,
- the scope of the present invention also includes foods and beverages describing expressions suggestive of/inferred to improve blood pressure, such as “maintains normal blood pressure” and “improves blood pressure.”
- the blood sugar level-improving composition of the present invention it is “suitable for those who are concerned about blood sugar level”, “moderates rise in blood sugar level”, “maintains high blood sugar level at normal”, “blood sugar level
- the scope of the present invention also includes foods and beverages, etc. describing expressions that remind/similarize improvement of blood sugar levels, such as "Towards a higher level of blood sugar”.
- composition for improving liver function of the present invention food and drink, etc., describing expressions suggesting/inferring improvement of liver function, such as “maintaining a healthy liver” and “for those with higher liver function values,” are also included in the present invention. Included in the scope.
- serum iron-adjusting composition of the present invention food and drink, etc., which describe expressions that remind/similarize serum iron adjustment, such as "for those who are concerned about iron deficiency” and “for anemia countermeasures", are also included in the present invention. Included in the scope.
- the composition "contributes to bone health”, “maintains bone components”, “helps bone metabolism”, “maintains strong bones”, and “prevents osteoporosis”.
- the scope of the present invention also includes foods and beverages, etc. that describe expressions suggesting/inferring promotion of calcium absorption, such as "because it is not possible”.
- composition of the present invention is not particularly limited, but is preferably human.
- the composition of the present invention can be taken by healthy individuals for daily health promotion as well as those concerned about uric acid level, blood pressure, blood sugar level, liver function, anemia, or bone health.
- Production example 1 Commercially available phytic acid solution (trade name: phytic acid (IP6), Tsukino Foods Industry Co., Ltd.) 108 mL (containing 75 g of phytic acid) and 1362 mL of Milli-Q water are mixed, and the water temperature is 40-60 ° C. for several minutes. Stir well. A magnetic stirrer was used for stirring (same below). 8.4 g of Ca(OH) 2 was added to the resulting diluted phytic acid solution and stirred well at a water temperature of 35-55° C. for about 10-40 minutes until completely dissolved. Further, 26.5 g of Mg(OH) 2 was added and stirred well for 10-40 minutes at a water temperature of 30-50°C.
- IP6 phytic acid
- Tsukino Foods Industry Co., Ltd. 108 mL (containing 75 g of phytic acid) and 1362 mL of Milli-Q water are mixed, and the water temperature is 40-60 ° C. for several minutes. Stir
- Test Example 1 Solubility Phytic acid and various minerals were mixed in water, and the solubility of each phytin having a predetermined molar ratio was examined from the turbidity of the resulting mixture.
- ⁇ Test method> (Sample preparation) Ca(OH) 2 (Inoue Lime Industry Co., Ltd.) as a calcium source, Mg(OH) 2 (Tomita Pharmaceutical Co., Ltd.) as a magnesium source, and potassium source in a 50 mL PP tube (IWAKI) at a room temperature of 20 to 25 ° C.
- Test Example 2 Effect of molar ratio of minerals in phytin on purine nucleotide metabolism inhibitory activity (sample preparation)
- a 50 mL PP tube IWAKI
- Ca(OH) 2 Inoue Lime Industry Co., Ltd.
- Mg(OH) 2 Tomita Pharmaceutical Co., Ltd.
- Table 2 Effect of molar ratio of minerals in phytin on purine nucleotide metabolism inhibitory activity
- a sample solution containing As a positive control a sample solution containing commercially available phytin (Phytin (IP6), Tsuno Foods Industry Co., Ltd.) was also prepared so that the content of phytic acid was the same as that of the other samples. (turbidity measurement and visual test) Each sample solution obtained above was stirred for 30 seconds, and turbidity measurement (Molecular Devices) was performed according to the solubility test method of the Japanese Code of Food Additives (9th edition, 2018). The absorbance at 600 nm of the standard solution "almost clear” was 0.008. The sample was visually observed to evaluate the presence or absence of precipitation of phytin.
- Phytin (IP6) Tsuno Foods Industry Co., Ltd.
- Detector SPD-M30A (Shimadzu Corporation) Column: COSMOSIL PAQ (4.6 mm ID ⁇ 150 mm, Nacalai Tesque Co., Ltd.) Mobile phase: 50 mM KH2PO4 (pH 7.5) Flow rate: 1.0 mL/min, detection wavelength: 254 nm, column temperature: 35°C Sample injection volume: 10 ⁇ L, pH: 6.4 The results are shown in Figures 2-1 to 2-5.
- DE3 which contains only 4 mol of magnesium as a mineral component with respect to 1.8 mol of phytic acid, showed an increase in inhibitory activity about 1.3 times that of phytic acid.
- DE4 containing 1 mol of sodium as a mineral component per 1.8 mol of phytic acid showed no change in inhibitory activity compared to phytic acid.
- DE5 containing 1 mol of potassium as a mineral component relative to 1.8 mol of phytic acid showed no change in inhibitory activity compared to phytic acid.
- the enzyme inhibitory activities of the water-soluble phytins Mg-01, Ca-01, K-02, Na-02, DE1 (they have the same composition), K-01, Na-01, Na-03, DE2, and DE3 are higher than that of phytic acid.
- Test Example 3 Stability of commercial products (deliquescent)
- powdered phytic acid (trade name: powdered phytic acid, Fuso Chemical Industry Co., Ltd.)
- phytin trade name: Phytin (IP6), Tsuno Foods Industry Co., Ltd., powder) were added at a humidity of 11.2% each. , 32.8%, 52.9%, 75.3%, and 97.3% for 64 hours, and the state was visually observed.
- Each test humidity environment is lithium chloride (equilibrium relative humidity (ERH): 11.2), magnesium chloride (ERH: 32.8), magnesium nitrate (ERH: 52.9), sodium chloride (ERH: 75) in a desiccator.
- Test Example 4 Stability (Deliquescence) (Sample preparation) Ca(OH) 2 (Inoue Lime Industry Co., Ltd.) as a calcium source and Mg(OH) 2 (Tomita Seiyaku Co., Ltd.) as a magnesium source were placed in a 50 mL PP tube (IWAKI) at the molar ratios shown in Table 3 below. ), KOH (Nippon Soda Co., Ltd.) as a potassium source, and NaOH (TOSOH Co., Ltd.) as a sodium source were weighed, and 0.426 mL of phytic acid (phytic acid (IP6), Tsuno Foods Industry Co., Ltd.) was added thereto.
- phytic acid phytic acid (IP6), Tsuno Foods Industry Co., Ltd.
- phytic acid powdered phytic acid
- commercially available powdered phytic acid trade name: powdered phytic acid, Fuso Chemical Industry Co., Ltd.
- phytin Phytin (IP6), Tsuno Food Industry Co., Ltd.
- Test method A saturated aqueous solution of sodium chloride was placed in a desiccator and allowed to stand at a temperature of 25° C. to adjust the humidity to 75.3%.
- phytin of various mineral compositions including water-soluble phytin was placed in a petri dish (MS-11350: SUMILON). 200 mg was added, placed in a desiccator, and allowed to stand for 64 hours. After standing still, if a change in the state of the entire product that looks like starch syrup occurs, the product is "yes" deliquescent. I judged.
- Table 3 shows the results. Phytic acid and powdered phytic acid used as positive controls deliquesced to become starch syrup. On the other hand, phytin in samples 1 to 21 had no deliquescence, or only partially deliquesced and solidified, indicating that it is more stable in terms of deliquescence than phytic acid.
- a stability tester ETAC LABONIC LX330, Kusumoto Kasei
- thermostat Incubator IS82, Yamato Scientific
- the phytate of the present invention is particularly useful for formulations that require good water solubility, such as liquid formulations and granules to be dissolved in water before use.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
フィチン酸は通常液体の状態であるが、より加工しやすい様にフィチン酸に賦形剤等を加えた粉末フィチン酸(フィチン酸粉末品(50%))の形状で市販されている。しかしながら、当該粉末フィチン酸は潮解性で安定性に乏しいため、フィチン酸を酢酸ナトリウム粉末に密着した状態で存在させた安定化粉末状フィチン酸組成物などの安定化の取り組みが行われている(特許文献3)。
一方、フィチン酸のカルシウム・マグネシウム等のミネラル塩であるフィチンは粉末の状態で市販されているが潮解せずに安定である。フィチンとはミネラル塩の総称であって、そのカルシウム、マグネシウム等のミネラル成分の種類やモル比が一定ものを意味するものではなく、実際、米、トウモロコシ、小麦、オーツ麦等の天然に存在するフィチン中のマグネシウム、カルシウム等のミネラル成分のモル比は一定ではない(非特許文献1)。フィチンはその構成成分たるフィチン酸に起因する各種薬理/健康増進効果が期待されるものの、これまでに知られるフィチンはいずれも水に溶解せず(非特許文献2)、液体製剤、使用時に水に溶解して摂取する顆粒剤など、良好な水溶性が求められる製剤への使用には不適である。
〔2〕 フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(例えば0.5≦1.4x+y≦5.4、0.8≦1.4x+y≦5.4、1≦1.4x+y≦5.4)(x≧0、y≧0、ただし、xおよびyは共には0でない)である、〔1〕に記載のフィチン。
〔3〕 (A)カルシウムおよび/または(B)マグネシウムを含むフィチンであって、該フィチンにおいて、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、0≦x≦2(例えば、0.5≦x≦1.5)であり、0≦y≦6(例えば、0.5≦y≦5.5、1≦y≦4.5)であり、かつxおよびyは共には0でない、フィチン。
〔4〕 x+y>0.5(例えばx+y≧1.0)である、〔2〕または〔3〕に記載のフィチン。
〔5〕 0.3≦x≦1.07であり、かつ3.9≦y≦4.98である、〔2〕~〔4〕のいずれか1項に記載のフィチン。
〔6〕 0.65≦x≦1.07であり、かつ3.9≦y≦4.4である、〔2〕~〔5〕のいずれか1項に記載のフィチン。
〔7〕 0.9≦x≦1.1であり、かつ3.9≦y≦4.1である、〔3〕~〔4〕のいずれか1項に記載のフィチン。
〔8〕 (C)カリウムおよび/または(D)ナトリウムをさらに含有する、〔1〕~〔7〕のいずれか1項に記載のフィチン。
〔9〕 フィチン酸1.8モルあたりの(C)カリウムの物質量をpモル、(D)ナトリウムの物質量をqモルとしたとき、0≦p≦4(例えば、0.5≦p≦3、0.5≦p≦2、0.5≦p≦1.5、0.5≦p≦1.2)であり、0≦q≦6(例えば、0.5≦q≦3、0.5≦q≦2、0.5≦q≦1.5、0.5≦q≦1.2)であり、かつpおよびqは共には0でない、〔8〕に記載のフィチン。
〔10〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、組成物。
〔11〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、プリン体吸収抑制組成物。
〔12〕 該プリン体吸収が腸管からの吸収である、〔11〕に記載のプリン体吸収抑制組成物。
〔13〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、プリンヌクレオチド代謝阻害組成物。
〔14〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、フォスファターゼ阻害組成物。
〔15〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、尿酸値上昇抑制組成物。
〔16〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、血圧改善組成物。
〔17〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、血糖値改善組成物。
〔18〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、高カルシウム尿症予防組成物。
〔19〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する、脂質改善組成物。
〔20〕 固体製剤(例えば、粉剤、顆粒剤、タブレット、錠剤)である、〔10〕~〔19〕のいずれか1項に記載の組成物。
〔21〕 フィチン酸に水の存在下でカルシウム源(例えばCa(OH)2)およびマグネシウム源(例えばMg(OH)2)を添加することを含み、フィチン酸1.8モルあたりに添加される(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(例えば0.5≦1.4x+y≦5.4、0.8≦1.4x+y≦5.4、1≦1.4x+y≦5.4)(x≧0、y≧0、ただし、xおよびyは共には0でない)である、フィチンの水への溶解性を向上する方法。
〔22〕
フィチン酸;および
カルシウム源(例えばCa(OH)2)および/またはマグネシウム源(例えばMg(OH)2);
を水の存在下で混合する混合工程、および
得られた混合物を乾燥する乾燥工程
を含み、
該混合物中、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(例えば0.5≦1.4x+y≦5.4、0.8≦1.4x+y≦5.4、1≦1.4x+y≦5.4)(x≧0、y≧0、ただし、xおよびyは共には0でない)である、フィチンの製造方法。
〔23〕
フィチン酸;および
マグネシウム源(例えばMg(OH)2)および/またはカルシウム源(例えばCa(OH)2);
を水の存在下で混合する混合工程、および
得られた混合物を乾燥する乾燥工程
を含み、
該混合物中、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、0≦x≦2(例えば、0.5≦x≦1.5)であり、0≦y≦6(例えば、0.5≦y≦5.5、1≦y≦4.5)であり、かつxおよびyは共には0でない、フィチンの製造方法。
〔24〕x+y>0.5(例えばx+y≧1.0)である、〔21〕~〔23〕のいずれか1項に記載の方法。
〔25〕 0.3≦x≦1.07であり、かつ3.9≦y≦4.98である、〔21〕~〔24〕のいずれか1項に記載の方法。
〔26〕 0.65≦x≦1.07であり、かつ3.9≦y≦4.4である、〔21〕~〔25〕のいずれか1項に記載の方法。
〔27〕 0.9≦x≦1.1であり、かつ3.9≦y≦4.1である、〔23〕に記載の方法。
〔28〕 該混合工程において、
フィチン酸;および
マグネシウム源(例えばMg(OH)2)および/またはカルシウム源(例えばCa(OH)2);
を水および賦形剤の存在下で混合する、〔22〕~〔27〕のいずれか1項に記載の製造方法。
〔29〕 該混合工程において、
フィチン酸;
マグネシウム源(例えばMg(OH)2)および/またはカルシウム源(例えばCa(OH)2);および
カリウム源(例えばKOH)および/またはナトリウム源(例えばNaOH)を
を水の存在下で混合する、〔22〕~〔28〕のいずれか1項に記載の製造方法。
〔30〕 該混合工程において
フィチン酸;
マグネシウム源(例えばMg(OH)2)および/またはカルシウム源(例えばCa(OH)2);および
カリウム源(例えばKOH)および/またはナトリウム源(例えばNaOH):
を水および賦形剤の存在下で混合する、〔22〕~〔29〕のいずれか1項に記載の製造方法。
〔31〕 該混合物中、フィチン酸1.8モルあたりの(C)カリウムの物質量をpモル、(D)ナトリウムの物質量をqモルとしたとき、0≦p≦4(例えば、0.5≦p≦3、0.5≦p≦2、0.5≦p≦1.5、0.5≦p≦1.2)であり、0≦q≦6(例えば、0.5≦q≦3、0.5≦q≦2、0.5≦q≦1.5、0.5≦q≦1.2)であり、かつpおよびqは共には0でない、〔29〕または〔30〕に記載の製造方法。
〔32〕該賦形剤が、デキストリン、澱粉類、セルロース、糖類(例えば、乳糖、白糖、トレハロース)およびその任意の組み合わせから選択される、〔28〕、〔30〕、および〔31〕のいずれか1項に記載の製造方法。
〔33〕 ミネラル成分としてカルシウムのみを含有する水溶性フィチンを含有する、プリン体吸収抑制組成物。
〔34〕 水溶性フィチンにおけるモル比が、フィチン酸:カルシウム=1.8:0.1~4.0(モル)である、〔33〕に記載プリン体吸収抑制組成物。
〔35〕 プリン体吸収抑制組成物、プリンヌクレオチド代謝阻害組成物、フォスファターゼ阻害組成物、尿酸値上昇抑制組成物、血圧改善組成物、血糖値改善組成物、肝機能改善組成物、血清鉄調整組成物、カルシウム吸収促進組成物、高カルシウム尿症予防組成物、脂質改善組成物の製造における、〔1〕~〔9〕のいずれか1項に記載のフィチンの使用。
〔36〕 〔1〕~〔9〕のいずれか1項に記載のフィチンを含有する組成物を投与することを含む、プリン体の吸収を抑制する方法、プリンヌクレオチド代謝を阻害する方法、フォスファターゼを阻害する方法、尿酸値上昇を抑制する方法、血圧を改善する方法、血糖値を改善する方法、肝機能を改善する方法、血清鉄を調整する方法、またはカルシウム吸収を促進する方法、高カルシウム尿症を予防する方法、脂質レベルを改善する方法、脂質レベルの悪化を予防する方法。
〔37〕 プリン体吸収抑制、プリンヌクレオチド代謝阻害、フォスファターゼ阻害、尿酸値上昇抑制、血圧改善、血糖値改善、肝機能改善、血清鉄調整、カルシウム吸収促進、高カルシウム尿症予防または脂質改善における使用のための、〔1〕~〔9〕のいずれか1項に記載のフィチン。
前記〔1〕から〔37〕の各構成は、任意に2以上を選択して組み合わせることができる。
あるいは、フィチンを水(20~25℃)に加え(10mg/ml)、30秒間ヴォルテックスして60秒間ソニケーションする混合操作を計3回繰り返し、目視により沈殿が確認できないフィチンを意味しうる。
本発明の水に対する溶解性が向上したフィチンには、当該フィチンが水に対する溶解性の向上を示す限り、カルシウムおよびマグネシウムに加えて、他のミネラル成分(例えばカリウムおよびナトリウム)が含有されていてもよい。
本発明の水溶性フィチンには、当該フィチンが水溶性を示す限り、カルシウムおよびマグネシウムに加えて、他のミネラル成分(例えばカリウムおよびナトリウム)が含有されていてもよい。
一般的に従来のフィチンの物性は、白色の非水溶性の中性粉末であり、非潮解性で安定性に優れる。
フィチン酸;および
マグネシウム源および/またはカルシウム源;
を水の存在下で混合する混合工程、および
得られた混合物を乾燥する乾燥工程
を含む、フィチンの製造方法(以下、本願発明の製造方法と称する場合がある)を提供する。
従来よりフィチンは食経験が豊富で安全性が高い物質であり長期的かつ継続的な摂取に適する。本発明によれば、粉末組成物等の固体組成物にすることで携帯性の向上により利便性が上がるため、より長期的かつ継続的な摂取を可能にしうる。
本発明の1つの実施形態において、y=0である。
本発明のフィチンは、本発明の作用効果を阻害しない範囲で、カルシウム(A)及びマグネシウム(B)以外のミネラル成分を含有していてもよい。
1つの実施形態において、本発明のフィチンは、カルシウム、マグネシウム、カリウム、およびナトリウム以外のミネラル成分を実質的に含まない。
本発明の組成物中(飲食品、医薬組成物等)に含まれるフィチンの量、1回の投与あたりに投与されるフィチンの量、および1日あたりに投与されるフィチンの量は、目的の効果が発揮される範囲であれば特に制限されず、組成物の形態や投与回数、対象の健康状態等に応じて適宜選択されうる。本発明の組成物の投与期間は目的の効果が発揮される範囲であれば特に制限されず、単回であっても、継続的に投与されても良い。例えば、プリン体吸収抑制、プリンヌクレオチド代謝阻害、フォスファターゼ阻害、尿酸値上昇抑制、血圧改善、血糖値改善、肝機能改善、血清鉄調整、またはカルシウム吸収促進等の効果を継続的に得るために、本発明の組成物は長期間にわたり継続して摂取されることが望ましく、例えば2日間、3日間、1週間、10日間、1箇月、または3箇月以上されうる。
本発明の組成物に配合されるフィチンの量としては、フィチンの種類、および該組成物の形態等によっても異なるが、例えば、該組成物の総重量に対して、通常フィチンとして0.1重量%~90重量%の範囲から適宜選択することができる。例えば0.5重量%~90重量%、0.5重量%~85重量%、0.5重量%~80重量%、1重量%~70重量%、および1重量%~50重量%が例示される。
本願の組成物に含まれるフィチンの含量の上限値の更なる例として、該組成物の総重量に対して、90重量%、85重量%、80重量%、70重量%、50重量%、30重量%、10重量%、および5重量%が挙げられ;本願の組成物に含まれるフィチンの含量の下限値の更なる例として、該組成物の総重量に対して、0.1重量%、0.5重量%、0.7重量%、および1重量%が挙げられ;本発明の組成物に配合されるフィチンの量の好ましい範囲は該上限値と該下限値の組合せにより示されうる。
本発明の組成物が錠剤、顆粒剤、カプセル剤、粉末剤、チュアブル錠等の固形製剤として製剤化される場合、本発明の組成物に配合されるフィチンの量としては、該組成物の総重量に対して、例えば、1~90重量%の範囲から適宜選択することができる。好ましい例として1重量%~90重量%、5重量%~80重量%、10重量%~70重量%、50重量%~70重量%が例示される。
本発明の組成物は、フィチンの種類によっても異なるが、フィチンは1回の投与あたり、例えばフィチン酸として10mg~15g、好ましくは100mg~8g、さらに好ましくは300mg~5g投与され得る。フィチンの1回あたりの摂取量の下限値の例として、フィチン酸として10mg、100mg、300mg、500mg、および600mgが挙げられ、上限値の例として、フィチン酸として15g、10g、8g、5g、3g、2g、1g、600mgが挙げられ、フィチンの1回あたりの摂取量の好ましい範囲は該上限値と該下限値の組合せにより示されうる。
本発明の組成物に含まれるフィチンの含量は当業者に知られる一般的な分析方法で分析することができる。これらに限定されるものではないが、例えばイオンクロマト法およびバナドモリブデン酸吸光度法が挙げられる。
本発明の組成物の摂取のタイミングは特に限定されないが、食事と共に、または食前または食後の30分以内に摂取されることが好ましい。
本発明の組成物は経口摂取製剤として製剤化されることが好ましく、その製剤型は特に限定されないが、例えば、錠剤、顆粒剤、カプセル剤、粉末剤、チュアブル錠、菓子類(クッキー、ビスケット、チョコレート菓子、チップス、ケーキ、ガム、キャンディー、グミ、饅頭、羊羹、プリン、ゼリー、ヨーグルト、アイスクリーム、シャーベットなど)、パン、麺類、ご飯類、シリアル食品、粉末飲料、スープ(粉末、フリーズドライ)、味噌汁(粉末、フリーズドライ)、通常の食品形態であり得る。
本発明の組成物の投与対象は特に限定されないが、好ましくはヒトである。本発明の組成物は尿酸値、血圧、血糖値、肝機能、貧血、または骨の健康が気になる者に加え、日々の健康増進のために健康な者によっても摂取されうる。
市販のフィチン酸溶液(商品名:フィチン酸(IP6),築野食品工業(株))108mL(フィチン酸として75g含有)と1362mLのMilli-Q水を混合し、水温40-60℃で数分間よく撹拌した。攪拌にはマグネットスターラーを使用した(以下同様)。得られたフィチン酸希釈溶液に8.4gのCa(OH)2を添加し、水温35-55℃で10-40分程度完全に溶解するまでよく撹拌した。更に、26.5gのMg(OH)2を入れ、水温30-50℃で10-40分程度よく撹拌した。最後に30mLの3.79M KOH・NaOH水溶液を少量ずつ入れ、水温25-45℃で10-40分程度よく撹拌した。得られた混合液に新たに調整したフィチン酸溶液((商品名:フィチン酸(IP6),築野食品工業(株))86mL(フィチン酸として60g含有)と1114mLのMilli-Q水を混合したもの)を添加後よく撹拌し、塩酸を加えてpH4.0±0.2となるように調整し、30-120分間良く攪拌した。
得られた混合液にデキストリンを84.0g加えて30-90分間よく攪拌し、適切な容器に入れて、凍結乾燥し、フィチン(フィチン酸1.8モルに対してMg:K:Na:Ca=4:1:1:1(モル))を得た。
フィチン酸と各種ミネラルを水中で混合し、得られた混合液の濁度により、所定のモル比を有する各フィチンの溶解性を調べた。
<試験方法>
(サンプル調製)
室温20~25℃で、50mLのPPチューブ(IWAKI)にカルシウム源としてCa(OH)2(井上石灰工業(株)),マグネシウム源としてMg(OH)2(富田製薬(株)),カリウム源としてKOH(日本曹達(株)),ナトリウム源としてNaOH(TOSOH(株))を下表に従い添加し、さらに市販のフィチン酸溶液(商品名:フィチン酸(IP6),築野食品工業(株))0.426mL(フィチン酸として0.296g含有)を添加した後、蒸留水((株)大塚製薬工場)を添加して30mlにメスアップした。ボルテックス・ミキサーを用いて30秒間の撹拌後,60秒間超音波処理(ASONE)を行った。この撹拌および超音波処理の操作を計3回繰り返した。
(濁度測定および目視試験)
上記で得られた各サンプルを30秒間撹拌し,食品添加物公定書(第9版、2018)の溶状試験法に準じて濁度測定(Molecular Devices)を行った。標準液「ほとんど透明」の600nmにおける吸光度は0.008であった。
当該サンプルを目視にて観察し、フィチンの析出の有無を評価した。
〇:析出なし。
×:析出あり。
吸光度が0.008以下であり、かつ、目視による観察で析出が認められなかった場合を「水溶性」とした。それ以外を「非水溶性」とした。
下表および図1に結果を示す。
フィチン酸1.8モルあたりのカルシウムの物質量をxモル、マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4を満たすフィチンはいずれも水溶性を示した。
試験例1で得られた各サンプルを凍結乾燥し、表1に示すモル比を有する各フィチン(粉末)を得た。
(サンプル調製)
50mLのPPチューブ(IWAKI)に下記表2に示すモル比になるようにカルシウム源としてCa(OH)2(井上石灰工業(株)),マグネシウム源としてMg(OH)2(富田製薬(株)),カリウム源としてKOH(日本曹達(株)),ナトリウム源としてNaOH(TOSOH(株))を秤量し、そこにフィチン酸溶液(商品名:フィチン酸(IP6),築野食品工業(株))0.426mL(フィチン酸として0.296g含有)を添加した。更に蒸留水((株)大塚製薬工場)を添加して30mLにメスアップし、ボルテックス・ミキサーを用いて30秒間の撹拌後,60秒間超音波処理(ASONE)を行い、各種ミネラル組成のフィチンを含む検体液を調製した。また陽性対照として、市販のフィチン(フィチン(IP6),築野食品工業(株))を含む検体液もフィチン酸としての含有量が他の検体と同じとなる濃度に調製した。
(濁度測定および目視試験)
上記で得られた各検体液を30秒間撹拌し,食品添加物公定書(第9版、2018)の溶状試験法に準じて濁度測定(Molecular Devices)を行った。標準液「ほとんど透明」の600nmにおける吸光度は0.008であった。
当該サンプルを目視にて観察し、フィチンの析出の有無を評価した。
吸光度が0.008以下であり、かつ、目視による観察で析出が認められなかった場合を「水溶性」とした。それ以外を「非水溶性」とした。
結果を表2に示す。
(プリンヌクレオチド代謝阻害活性 試験方法)
ラット小腸粉末(日本クレア(株))をアッセイバッファーで100mg/mLに調製したものを酵素液とした。Inosine monophosphate(Sigma-Aldrich)をアッセイバッファーで9mMに調製したものを基質液とした。96穴プレート(Thermo Fisher Scientific)を用いて以下の方法で酵素反応を行った。検体液(100μL/well),基質液(100μL/well)および酵素液(100μL/well)を添加し,37℃,30分間の酵素反応を行った。反応液を20μL分取し,マルチスクリーンHTS HV(Merck Millipore)に移し,停止液(0.33M HClO4,180μl/well)を添加し,反応を停止させた。遠心分離し(1080×g,10分間,室温),ろ液を高速液体クロマトグラフィー(HPLC)の試料とした。HPLCの分析条件を下記に示した。
検出器:SPD―M30A((株)島津製作所)
カラム:COSMOSIL PAQ(4.6mm I.D.×150mm,ナカライテスク(株))
移動相:50mM KH2PO4(pH7.5)
流速:1.0mL/min,検出波長:254nm,カラム温度:35℃
試料注入量:10μL,pH:6.4
結果を図2-1~図2-5に示す。
フィチン酸の酵素阻害活性が30%前後であって、フィチンの阻害活性がフィチン酸と比べて有意に低い条件下において、フィチン酸(商品名:フィチン酸(IP6),築野食品工業(株))との酵素阻害活性の比較試験を行った。
フィチン酸1.8モルに対してマグネシウムを4モル含むMg-01では有意な活性の上昇が認められた。一方、マグネシウムがそれぞれ6、8、12、16、および20モルであるMg-02~06ではマグネシウムのモル比に反比例して、有意な阻害活性の低下が認められた。
フィチン酸1.8モルに対してカルシウム1、2、4、および8モルをそれぞれ含有するCa-01~04では活性の上昇がみられた。
フィチン酸1.8モルに対してナトリウムを0、1、2、4、6、12、16、および20モルそれぞれ含有するNa-01~08の結果から、ナトリウムの添加による阻害活性への影響は認められなかった。
フィチン酸1.8モルに対してカリウムを0、1、4、8、12、16、および20モルそれぞれ含有するK-01~07の結果から、カリウムの添加による阻害活性への影響は認められなかった。
フィチン酸1.8モルに対してミネラル成分としてカルシウムのみを1モル含有するDE2ではフィチン酸よりも約1.9倍の有意な阻害活性の上昇が認められた。
フィチン酸1.8モルに対してミネラル成分としてマグネシウムのみを4モル含有するDE3ではフィチン酸よりも約1.3倍の阻害活性の上昇が認められた。
フィチン酸1.8モルに対してミネラル成分としてナトリウムのみを1モル含有するDE4ではフィチン酸と比較して阻害活性に変化は認められなかった。
フィチン酸1.8モルに対してミネラル成分としてカリウムのみを1モル含有するDE5ではフィチン酸と比較して阻害活性に変化は認められなかった。
水溶性フィチンであるMg-01、Ca-01、K-02、Na-02、DE1(これらは同一組成)、K-01、Na-01、Na-03、DE2、およびDE3の酵素阻害活性はフィチン酸と比較して高かった。
市販の粉末フィチン酸(商品名:粉末フィチン酸、扶桑化学工業(株))及び市販のフィチン(商品名:フィチン(IP6)、築野食品工業(株)、粉末)を各湿度11.2%,32.8%,52.9%,75.3%,97.3%で64時間放置し、その状態を目視で観察した。各試験湿度環境は、デシケーター内に塩化リチウム(平衡相対湿度(ERH):11.2)、塩化マグネシウム(ERH:32.8)、硝酸マグネシウム(ERH:52.9)、塩化ナトリウム(ERH:75.3)及び硫酸カリウム(ERH:97.3)の各飽和水溶液を入れ、温湿度計を設置し、温度25度で静置することで作成した。
その結果、粉末フィチン酸は湿度32.8%で固化し、52.9%以上で水飴状等に液状化した。一方、フィチンはいずれの湿度条件下においても、変化は見られなかった。
(サンプル調製)
50mLのPPチューブ(IWAKI)に下記表3に示すモル比になるようにカルシウム源としてCa(OH)2(井上石灰工業(株)),マグネシウム源としてMg(OH)2(富田製薬(株)),カリウム源としてKOH(日本曹達(株)),ナトリウム源としてNaOH(TOSOH(株))を秤量し、そこにフィチン酸(フィチン酸(IP6),築野食品工業(株))0.426mL(フィチン酸として0.296g含有)を添加した。更に蒸留水((株)大塚製薬工場)を添加して30mLにメスアップし、ボルテックス・ミキサーを用いて30秒間の撹拌後,60秒間超音波処理(ASONE)を行った。この撹拌と超音波処理の操作を計3回繰り返した。ついで塩酸を用いてpHを4.0±0.2に調整し、-80℃にて予備凍結した。凍結乾燥機を用いて、完全に粉体化させたフィチンを得、検体として用いた。
また陽性対照として、上記手順においてミネラル成分を加えずに調製したフィチン酸(粉末)と、市販の粉末フィチン酸(商品名:粉末フィチン酸、扶桑化学工業(株))を用いた。さらに陰性対照として、市販のフィチン(フィチン(IP6),築野食品工業(株))を用いた。
(試験方法)
デシケーター内に塩化ナトリウム飽和水溶液を入れ、温度25度で静置することで湿度が75.3%になるようにした。試験例1の結果から水溶性を示す範囲のフィチン
(具体的にはサンプル2、3、6-9、および12-21)を含む各種ミネラル組成のフィチンをシャーレ(MS-11350:SUMILON)に約200mg入れし、デシケーターに入れて,64時間静置した。静置後、目視により全体が水飴状になるような状態変化が起きれば潮解性「あり」、一部に潮解や固化が見られた場合を「一部あり」、変化がければ「なし」と判定した。
結果を表3に示した。
陽性対照としたフィチン酸及び粉末フィチン酸では潮解して水飴状となった。
一方、サンプル1~21のフィチンでは、潮解性なしであるか、あるいは一部潮解や固化が見られるのみであり、フィチン酸と比較して、潮解性に関し安定であることが示された。
(サンプル調製)
製造例1の方法で得られた水溶性フィチン(フィチン酸1.8モルに対するモル比が、Mg:Ca:Na:K=4:1:1:1、デキストリン添加濃度67%)の長期保存安定性試験を実施した。具体的には、安定性試験器(ETAC LABONIC LX330、楠本化成)にて温度25℃、湿度60%で保管した場合と、恒温器(Incubator IS82、ヤマト科学)にて温度40℃、湿度75%で保管した場合の当該フィチンの水分活性を経時的に3カ月まで測定した。水分活性測定は測定機器(LabMster-aw Basic、Novasina)を用いて測定温度25℃で実施した。またその状態を目視にて観察した。
保管条件と水分活性及び性状の結果を下表4に示した。高湿度条件下で保管する前の水溶性フィチンの水分活性は0.020であるのに対し、温度25℃、湿度60%で保管した場合では0.027-0.030、温度40℃、湿度75%で保管した場合では0.034-0.047と経時的にわずかに増加した。しかしながら、それらの値は、一般的に食品中で微生物が繁殖しない、つまり吸湿していない状態の水分活性である0.5以下と比較して、10分の1以下であることから、当該フィチンの吸湿は僅かであると言える。また性状については、白色粉末で潮解することはなかった。以上の結果から、当該フィチンは粉末状で長期間安定に存在し得ることが分かった。
Claims (37)
- (A)カルシウムおよび/または(B)マグネシウムを含む水溶性フィチン。
- フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(x≧0、y≧0、ただし、xおよびyは共には0でない)である、請求項1に記載のフィチン。
- (A)カルシウムおよび/または(B)マグネシウムを含むフィチンであって、該フィチンにおいて、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、0≦x≦2であり、0≦y≦6であり、かつxおよびyは共には0でない、フィチン。
- x+y>0.5である、請求項2または3に記載のフィチン。
- 0.3≦x≦1.07であり、かつ3.9≦y≦4.98である、請求項2~4のいずれか1項に記載のフィチン。
- 0.65≦x≦1.07であり、かつ3.9≦y≦4.4である、請求項2~5のいずれか1項に記載のフィチン。
- 0.9≦x≦1.1であり、かつ3.9≦y≦4.1である、請求項3~4のいずれか1項に記載のフィチン。
- (C)カリウムおよび/または(D)ナトリウムをさらに含有する、請求項1~7のいずれか1項に記載のフィチン。
- フィチン酸1.8モルあたりの(C)カリウムの物質量をpモル、(D)ナトリウムの物質量をqモルとしたとき、0≦p≦4であり、0≦q≦6であり、かつpおよびqは共には0でない、請求項8に記載のフィチン。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、プリン体吸収抑制組成物。
- 該プリン体吸収が腸管からの吸収である、請求項11に記載のプリン体吸収抑制組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、プリンヌクレオチド代謝阻害組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、フォスファターゼ阻害組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、尿酸値上昇抑制組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、血圧改善組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、血糖値改善組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、高カルシウム尿症予防組成物。
- 請求項1~9のいずれか1項に記載のフィチンを含有する、脂質改善組成物。
- 固体製剤である、請求項10~19のいずれか1項に記載の組成物。
- フィチン酸に水の存在下でカルシウム源およびマグネシウム源を添加することを含み、フィチン酸1.8モルあたりに添加される(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(x≧0、y≧0、ただし、xおよびyは共には0でない)である、フィチンの水への溶解性を向上する方法。
- フィチン酸;および
カルシウム源および/またはマグネシウム源;
を水の存在下で混合する混合工程、および
得られた混合物を乾燥する乾燥工程
を含み、
該混合物中、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、1.4x+y≦5.4(x≧0、y≧0、ただし、xおよびyは共には0でない)である、フィチンの製造方法。 - フィチン酸;および
マグネシウム源および/またはカルシウム源;
を水の存在下で混合する混合工程、および
得られた混合物を乾燥する乾燥工程
を含み、
該混合物中、フィチン酸1.8モルあたりの(A)カルシウムの物質量をxモル、(B)マグネシウムの物質量をyモルとしたとき、0≦x≦2であり、0≦y≦6であり、かつxおよびyは共には0でない、フィチンの製造方法。 - x+y>0.5である、請求項21~23のいずれか1項に記載の方法。
- 0.3≦x≦1.07であり、かつ3.9≦y≦4.98である、請求項21~24のいずれか1項に記載の方法。
- 0.65≦x≦1.07であり、かつ3.9≦y≦4.4である、請求項21~25のいずれか1項に記載の方法。
- 0.9≦x≦1.1であり、かつ3.9≦y≦4.1である、請求項23に記載の方法。
- 該混合工程において、
フィチン酸;および
マグネシウム源および/またはカルシウム源;
を水および賦形剤の存在下で混合する、請求項22~27のいずれか1項に記載の製造方法。 - 該混合工程において、
フィチン酸;
マグネシウム源および/またはカルシウム源;および
カリウム源および/またはナトリウム源を
を水の存在下で混合する、請求項22~28のいずれか1項に記載の製造方法。 - 該混合工程において
フィチン酸;
マグネシウム源および/またはカルシウム源;および
カリウム源および/またはナトリウム源:
を水および賦形剤の存在下で混合する、請求項22~29のいずれか1項に記載の製造方法。 - 該混合物中、フィチン酸1.8モルあたりの(C)カリウムの物質量をpモル、(D)ナトリウムの物質量をqモルとしたとき、0≦p≦4であり、0≦q≦6であり、かつpおよびqは共には0でない、請求項29または30に記載の製造方法。
- 該賦形剤が、デキストリン、澱粉類、セルロース、糖類およびその任意の組み合わせから選択される、請求項28、30、および31のいずれか1項に記載の製造方法。
- ミネラル成分としてカルシウムのみを含有する水溶性フィチンを含有する、プリン体吸収抑制組成物。
- 水溶性フィチンにおけるモル比が、フィチン酸:カルシウム=1.8:0.1~4.0(モル)である、請求項33に記載プリン体吸収抑制組成物。
- プリン体吸収抑制組成物、プリンヌクレオチド代謝阻害組成物、フォスファターゼ阻害組成物、尿酸値上昇抑制組成物、血圧改善組成物、血糖値改善組成物、肝機能改善組成物、血清鉄調整組成物、カルシウム吸収促進組成物、高カルシウム尿症予防組成物、脂質改善組成物の製造における、請求項1~9のいずれか1項に記載のフィチンの使用。
- 請求項1~9のいずれか1項に記載のフィチンを含有する組成物を投与することを含む、プリン体の吸収を抑制する方法、プリンヌクレオチド代謝を阻害する方法、フォスファターゼを阻害する方法、尿酸値上昇を抑制する方法、血圧を改善する方法、血糖値を改善する方法、肝機能を改善する方法、血清鉄を調整する方法、またはカルシウム吸収を促進する方法、高カルシウム尿症を予防する方法、脂質レベルを改善する方法、脂質レベルの悪化を予防する方法。
- プリン体吸収抑制、プリンヌクレオチド代謝阻害、フォスファターゼ阻害、尿酸値上昇抑制、血圧改善、血糖値改善、肝機能改善、血清鉄調整、カルシウム吸収促進、高カルシウム尿症予防または脂質改善における使用のための、請求項1~9のいずれか1項に記載のフィチン。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020247011023A KR20240056735A (ko) | 2021-09-06 | 2022-09-05 | 수용성 피틴 |
JP2023545713A JPWO2023033174A1 (ja) | 2021-09-06 | 2022-09-05 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021144782 | 2021-09-06 | ||
JP2021-144782 | 2021-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023033174A1 true WO2023033174A1 (ja) | 2023-03-09 |
Family
ID=85412469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/033286 WO2023033174A1 (ja) | 2021-09-06 | 2022-09-05 | 水溶性フィチン |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2023033174A1 (ja) |
KR (1) | KR20240056735A (ja) |
TW (1) | TW202327623A (ja) |
WO (1) | WO2023033174A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2691035A (en) * | 1951-02-09 | 1954-10-05 | Staley Mfg Co A E | Preparation of phytic acid and soluble salts thereof |
US2718523A (en) * | 1951-01-25 | 1955-09-20 | Staley Mfg Co A E | Preparation of phytic acid and soluble salts thereof by cation exchange |
JP2000026109A (ja) * | 1998-07-10 | 2000-01-25 | Oji Cornstarch Kk | 水性溶液中の過酸化水素の安定化剤及び安定化方法 |
JP2010195734A (ja) * | 2009-02-26 | 2010-09-09 | Nisshin Pharma Inc | フィチン酸、カルボン酸、および糖類の相乗効果による脂肪吸収抑制作用を有する組成物 |
JP2012213380A (ja) | 2011-03-25 | 2012-11-08 | Hiroe Ogawa | 安定な粉末状フィチン酸組成物、その製造法及びそれを用いた食品の風味品質改良剤 |
JP2017039762A (ja) | 2016-10-20 | 2017-02-23 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
WO2019082335A1 (ja) | 2017-10-26 | 2019-05-02 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102005057B1 (ko) | 2017-11-29 | 2019-07-30 | 고진솔 | Ble 비콘 서비스의 선택적 수신 방법 및 이를 이용한 ble 비콘 서비스 시스템 |
-
2022
- 2022-09-05 JP JP2023545713A patent/JPWO2023033174A1/ja active Pending
- 2022-09-05 KR KR1020247011023A patent/KR20240056735A/ko unknown
- 2022-09-05 WO PCT/JP2022/033286 patent/WO2023033174A1/ja active Application Filing
- 2022-09-05 TW TW111133587A patent/TW202327623A/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2718523A (en) * | 1951-01-25 | 1955-09-20 | Staley Mfg Co A E | Preparation of phytic acid and soluble salts thereof by cation exchange |
US2691035A (en) * | 1951-02-09 | 1954-10-05 | Staley Mfg Co A E | Preparation of phytic acid and soluble salts thereof |
JP2000026109A (ja) * | 1998-07-10 | 2000-01-25 | Oji Cornstarch Kk | 水性溶液中の過酸化水素の安定化剤及び安定化方法 |
JP2010195734A (ja) * | 2009-02-26 | 2010-09-09 | Nisshin Pharma Inc | フィチン酸、カルボン酸、および糖類の相乗効果による脂肪吸収抑制作用を有する組成物 |
JP2012213380A (ja) | 2011-03-25 | 2012-11-08 | Hiroe Ogawa | 安定な粉末状フィチン酸組成物、その製造法及びそれを用いた食品の風味品質改良剤 |
JP2017039762A (ja) | 2016-10-20 | 2017-02-23 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
WO2019082335A1 (ja) | 2017-10-26 | 2019-05-02 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
Non-Patent Citations (4)
Title |
---|
"Clarity of Solution Test in Japan's Specifications and Standards for Food Additives", 2018 |
PLIMMER RH ET AL., BIOCHEM J., vol. 7, no. 2, 1913, pages 157 - 74 |
PLIMMER ROBERT HENRY ADERS, HAROLD JAMES PAGE: "XV. AN INVESTIGATION OF PHYTIN", BIOCHEM J., vol. 7, no. 2, 31 March 1913 (1913-03-31), pages 157 - 174, XP093043082, DOI: 10.1042/bj0070157 * |
YOSHIDA KTWADA TKOYAMA HMIZOBUCHI-FUKUOKA RNAITO S: "Temporal and spatial patterns of accumulation of the transcript of Myo-inositol-1-phosphate synthase and phytin-containing particles during seed development in rice", PLANT PHYSIOL., vol. 119, no. 1, 1999, pages 65 - 72, XP002417204, DOI: 10.1104/pp.119.1.65 |
Also Published As
Publication number | Publication date |
---|---|
KR20240056735A (ko) | 2024-04-30 |
JPWO2023033174A1 (ja) | 2023-03-09 |
TW202327623A (zh) | 2023-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9017745B2 (en) | Method of using isomaltulose to suppress body fat accumulation | |
JP5927663B2 (ja) | 血糖値の上昇が緩やかな糖質組成物及び飲食品 | |
EP3263118A1 (en) | Flaxseeds for body weight management | |
MXPA05003088A (es) | Composiciones nutricionales enriquecidas en leucina. | |
US20050101660A1 (en) | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease | |
US20220387464A1 (en) | Inositol phosphate-containing composition | |
JP2010178683A (ja) | 生体機能改善作用を持つd−ソルボース含有機能性甘味料およびそれを使用して得られた飲食品等 | |
ES2346864T3 (es) | Producto fibroso liquido caliente. | |
WO2023033174A1 (ja) | 水溶性フィチン | |
JP6391959B2 (ja) | 非アルコール性脂肪性肝炎の改善剤および改善用栄養組成物 | |
JP2008247858A (ja) | ダイエット用の経口摂取用組成物 | |
CN118159276A (zh) | 水溶性非丁 | |
KR102666724B1 (ko) | 이노시톨인산 함유 조성물 | |
JP7217089B2 (ja) | 血糖値上昇抑制剤及びこれを含んでなる経口組成物 | |
JP2007031445A (ja) | 血糖値上昇抑制剤及び体脂肪蓄積抑制剤並びに食用材料 | |
JP2003000196A (ja) | 糖尿病の治療・予防用食品 | |
WO2021255979A1 (ja) | 抗肥満用組成物及び経口用組成物 | |
US20200000834A1 (en) | Polyphenol glycoside-containing composition | |
JP4405308B2 (ja) | アルコール吸収抑制剤 | |
JP6458395B2 (ja) | 脂質燃焼促進剤及びそれを含む飲食品 | |
JP2022109162A (ja) | 食後の尿酸値上昇抑制用組成物 | |
JP2021187785A (ja) | 精神性疲労、意欲低下または眠気の改善剤 | |
JP5943516B2 (ja) | D−ソルボースを有効成分とする生体機能改善用甘味料 | |
JP2007099672A (ja) | 腸内硫化水素量低減組成物 | |
JPH1160478A (ja) | マグネシウム含有経口組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22864756 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023545713 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20247011023 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022864756 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022864756 Country of ref document: EP Effective date: 20240408 |